ID: ALA3297998

Max Phase: Preclinical

Molecular Formula: C19H23N3O2

Molecular Weight: 325.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCN(c1ccc(OC)cc1)c1nc(C)nc2oc(C)cc12

Standard InChI:  InChI=1S/C19H23N3O2/c1-5-6-11-22(15-7-9-16(23-4)10-8-15)18-17-12-13(2)24-19(17)21-14(3)20-18/h7-10,12H,5-6,11H2,1-4H3

Standard InChI Key:  FPTCDUYOZYIIST-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 325.41

Molecular Weight (Monoisotopic): 325.1790

AlogP: 4.79

#Rotatable Bonds: 6

Polar Surface Area: 51.39

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 2.17

CX LogP: 4.57

CX LogD: 4.57

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.65

Np Likeness Score: -0.78

References

1. Zhang X, Raghavan S, Ihnat M, Thorpe JE, Disch BC, Bastian A, Bailey-Downs LC, Dybdal-Hargreaves NF, Rohena CC, Hamel E, Mooberry SL, Gangjee A..  (2014)  The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.,  22  (14): [PMID:24890652] [10.1016/j.bmc.2014.04.049]

Source

Source(1):

• Scientific Literature